Functional Human Serum Albumin as a Dual Phototherapeutic Nanoplatform for Triple‐negative Breast Cancer Therapy and Metastasis Inhibition
Source abstract
Abstract
Abstract The major obstacles to triple‐negative breast cancer (TNBC) therapy are metastasis and mortality rates, leading to the failure treatment of traditional chemotherapy. Therefore, low toxicity drugs and more effective therapeutic approaches are greatly desired. Considering the drawbacks of indocyanine green (ICG) and purpurin such as poor bioavailability and rapid blood clearance, an endogenous carrier material human serum albumin (HSA) was employed to construct the nanoplatform through hydrophobic interaction with the inspiration of successful delivery of paclitaxel. Herein, we developed and fabricated a new self‐assembled albumin‐based drug delivery system (ICG‐purpurin@HSA, HIP) with encapsulation of ICG and purpurin. Of note, compared to free ICG and purpurin, enhanced treatment efficiency was achieved by the HIP with the help of reactive oxygen species (ROS)‐heat‐induced damage and nutrient supply cutoff. Consequently, an efficient drug delivery platform based on photothermal therapy (PTT) and photodynamic therapy (PDT) was proposed, revealing a promising strategy for TNBC treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Sciences and Health Engineering Jiangnan University 214122 Wuxi P. R. China
References (62)
Show source-provided references
1.
2. 10.3322/caac.2149210.3322/caac.21492 ↗
3. 10.1200/JCO.2005.05.230810.1200/JCO.2005.05.2308 ↗
4.
5. 10.1038/nbt0206-16310.1038/nbt0206-163 ↗
6. 10.1016/j.biopha.2021.11130210.1016/j.biopha.2021.111302 ↗
7. 10.1038/nrclinonc.2010.15410.1038/nrclinonc.2010.154 ↗
8.
9. 10.1038/nrd237210.1038/nrd2372 ↗
10. 10.2174/157340641266615111614402610.2174/1573406412666151116144026 ↗
11. 10.1002/adfm.20160430010.1002/adfm.201604300 ↗
12. 10.1002/adma.20140430810.1002/adma.201404308 ↗
13.
14. 10.1063/5.006153010.1063/5.0061530 ↗
15. 10.1002/adma.20211009410.1002/adma.202110094 ↗
16. 10.1021/acs.nanolett.0c0477810.1021/acs.nanolett.0c04778 ↗
17. 10.1002/adma.20200742610.1002/adma.202007426 ↗
18. 10.1016/j.ajps.2021.10.00410.1016/j.ajps.2021.10.004 ↗
19.
20. 10.1002/adma.20130189010.1002/adma.201301890 ↗
21. 10.1016/j.jcis.2021.03.05010.1016/j.jcis.2021.03.050 ↗
22. 10.1016/j.biopha.2021.11256410.1016/j.biopha.2021.112564 ↗
23.
24. 10.1021/acsbiomaterials.8b0037910.1021/acsbiomaterials.8b00379 ↗
25. 10.1016/j.biomaterials.2018.02.04110.1016/j.biomaterials.2018.02.041 ↗
26. 10.1021/acsami.9b0089710.1021/acsami.9b00897 ↗
27.
28. 10.1021/nn400334y10.1021/nn400334y ↗
29. 10.1016/j.jddst.2022.10352110.1016/j.jddst.2022.103521 ↗
30.
31. 10.1002/anie.20180513810.1002/anie.201805138 ↗
32. 10.1002/ange.20180513810.1002/ange.201805138 ↗
33. 10.1016/j.colsurfb.2020.11084210.1016/j.colsurfb.2020.110842 ↗
34. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
35.
36. 10.1021/nn506238610.1021/nn5062386 ↗
37. 10.1021/nn505729m10.1021/nn505729m ↗
38.
39. 10.7150/thno.1498810.7150/thno.14988 ↗
40. 10.1016/j.jconrel.2018.03.00910.1016/j.jconrel.2018.03.009 ↗
41. 10.2147/IJN.S31867810.2147/IJN.S318678 ↗
42. 10.1016/j.ccell.2014.12.00610.1016/j.ccell.2014.12.006 ↗
43. 10.1158/0008-5472.CAN-09-226610.1158/0008-5472.CAN-09-2266 ↗
44. 10.1038/onc.2015.44710.1038/onc.2015.447 ↗
45. 10.1126/science.aam930510.1126/science.aam9305 ↗
46. 10.1021/acs.nanolett.1c0207310.1021/acs.nanolett.1c02073 ↗
47.
48. 10.1021/acsbiomaterials.0c0028610.1021/acsbiomaterials.0c00286 ↗
49. 10.1002/adma.20160003810.1002/adma.201600038 ↗
50. 10.7150/thno.1936510.7150/thno.19365 ↗
51.
52. 10.1155/2014/18054910.1155/2014/180549 ↗
53. 10.1093/annonc/mdn66110.1093/annonc/mdn661 ↗
54. 10.1504/IJNM.2009.02811610.1504/IJNM.2009.028116 ↗
55. 10.1016/S1359-6349(10)70002-110.1016/S1359-6349(10)70002-1 ↗
56.
57. 10.1021/acsami.9b1126310.1021/acsami.9b11263 ↗
58. 10.1016/j.molliq.2015.04.05010.1016/j.molliq.2015.04.050 ↗
59. 10.1021/acsami.7b1192610.1021/acsami.7b11926 ↗
60.
61. 10.1016/j.nano.2019.10205810.1016/j.nano.2019.102058 ↗
62. 10.1039/c2jm16831f10.1039/c2jm16831f ↗